一种纳米膳食纤维及其制备、纳米膳食纤维载药系统及其制备与应用
By using an active targeted nanofiber drug delivery system, combined with IL-1beta antibody and Bifidobacterium, the problems of stability, time control and spatial obstacles of existing colorectal targeted nanocarriers have been solved, realizing targeted treatment of colorectal inflammation sites and improvement of intestinal function.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SUZHOU MUNICIPAL HOSPITAL
- Filing Date
- 2023-08-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing colorectal targeted nanocarriers have difficulty maintaining drug stability in gastric acid, the delivery time of targeted drugs is uncontrollable, and it is difficult to overcome spatial barriers to reach the designated site and release the drug. Furthermore, they do not improve the colorectal growth environment or the body's immune response.
The active targeted nanofiber drug delivery system uses IL-1 beta antibody attached to nanofibers to bind to Bifidobacteria, achieving targeted delivery to the site of colorectal inflammation. The nanofibers also perform physiological functions in the intestine, such as maintaining water content, increasing intestinal motility, neutralizing inflammatory factors, and restoring intestinal flora homeostasis.
It achieves targeted therapy of drugs at the site of colorectal inflammation, neutralizes inflammatory factors, improves the intestinal microenvironment, enhances immune resistance, reduces inflammation and tumor occurrence, and the nano-dietary fiber itself plays a variety of physiological functions in the intestine.
Smart Images
Figure CN117820507B_ABST